Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine
The STEP 1 trial compared once-weekly semaglutide with placebo alongside lifestyle intervention in adults with overweight or obesity without diabetes. It reports weight outcomes and adverse events in the studied population.
DOI: 10.1056/NEJMoa2032183